Exclusion Criteria:~* Significant neurological or psychiatric disease other than Alzheimer's disease~*
Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).~* Any
contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants).
Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor.~* Any
contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing
a PET scan.~* Previous exposure to investigational or non-investigational therapies for Alzheimer's disease
within 6 months of screening~* History of cancer within the last 5 years except adequately treated cervical
carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not
requiring treatment~* Women of childbearing potential~* Uncontrolled blood pressure and/or blood pressure above
160/100~* Prescription medical food intended for dietary management of the metabolic processes associated with
Alzheimer's disease.~* Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral
hemorrhage, intracranial tumor, subarachnoid hemorrhage.~* Patients with unstable, uncontrolled diabetes (HbA1c
> 7.7%) and those requiring insulin.
